Compare Citius Pharmaceuticals Inc (CTXR) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs JetBlue Airways Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while JetBlue Airways Corporation trades at $3.84 (market cap $1.48B). The key difference: JetBlue Airways Corporation is far larger — about 108.7× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 30,275,693). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and JetBlue Airways Corporation for 44 Days on average.
| CTXR | JBLU | |
|---|---|---|
Market Cap | $13.62M | $1.48B |
Volume | 132,438 | 30,275,693 |
Sector | Health | Industrials |
52-Week High | $1.82 | $6.46 |
52-Week Low | $0.48 | $3.92 |
Typical Hold Time | 17 Days | 44 Days |
Enterprise Value | $3.79M | $8.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
JetBlue (JBLU) trades at $3.92, down 1.26% with a bearish technical outlook. The airline faces fundamental challenges with negative net income margins (-9.32%) and declining revenue trends, though valuation metrics like P/S (0.15) appear attractive. Recent developments include route expansion to Colombia and new first-class seating, but the company continues to struggle with profitability amid high fuel costs and competitive pressures.
Investment outlook remains cautious with significant execution risks. While analyst consensus suggests moderate upside to the $5.89 price target, persistent losses and high debt levels (debt-to-asset ratio over 50%) create headwinds. The stock offers speculative value for investors betting on operational turnaround, but requires careful risk management given the challenging industry environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
